Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy
The FDA granted accelerated approval to Vera Therapeutics' TRUTAKNA (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy at risk of disease progression. The approval is based on the Phase 3 ORIGIN 3 trial, where TRUTAKNA achieved a statistically and clinically meaningful 42% reduction in proteinuria compared to placebo at 36 weeks.
Key figures
- Drug Name
- TRUTAKNA (atacicept-vymj)
- Phase Of Trial
- Phase 3
- Ig an us patients impacted est
- 160000
- Proteinuria reduction vs placebo
- 42%
- Proteinuria reduction from baseline
- 46%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.